Milestone Pharmaceuticals aims to treat Paroxysmal Supraventricular Tachycardia (PSVT) with their lead asset etripamil - an intranasally administered calcium channel blocker. After a recent CRL due to CMC concerns, Milestone is currently working to implement feedback and resubmit.
7 March 2025
Anavex Life Sciences is targeting Alzheimer’s Disease (AD) with their lead asset blarcamesine, an orally administered activator of the sigma-1 receptor. The company is currently awaiting the decision of the EMA, due in the first half of 2025. We express concerns regarding high drop out rates and apparent trial result obfuscation.
9 Jan 2025
HOLD
Abeona Therapeutics is targeting Recessive dystrophic epidermolysis bullosa with their pz-cel gene therapy. The next catalyst is their second PDUFA date, one year after they received a CRL from the FDA for the same treatment.
15 Apr 2025
SELLAS Life Sciences is targeting acute myeloid leukemia (AML) with their lead asset galinpepimut-s, a Wilm’s Tumour 1 (WT1) peptide vaccine. The next catalyst is the conclusion and readout of a Phase 3 trial.
26 Jan 2025
Coming Soon…
April 2025